Alliancebernstein L.P. Nuvation Bio Inc. Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

A detailed history of Alliancebernstein L.P. transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 197,389 shares of NUVB stock, worth $461,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,389

Previous 192,204 2.7%

Holding current value

$461,890

Previous $699,000 17.6%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.58 - $3.69 $13,377 - $19,132	5,185 Added 2.7%	197,389 $576,000
Q1 2024 May 14, 2024	SELL	$1.46 - $3.97 $11,066 - $30,092	-7,580 Reduced 3.79%	192,204 $699,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.53 $2,880 - $4,590	-3,000 Reduced 1.48%	199,784 $301,000
Q3 2023 Nov 14, 2023	BUY	$1.26 - $2.1 $7,018 - $11,697	5,570 Added 2.82%	202,784 $271,000
Q2 2023 Aug 15, 2023	BUY	$1.56 - $1.84 $26,551 - $31,316	17,020 Added 9.45%	197,214 $354,000
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $7,680 - $11,904	4,800 Added 2.74%	180,194 $299,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $20,832 - $31,000	12,400 Added 7.61%	175,394 $336,000
Q1 2022 May 13, 2022	SELL	$4.6 - $8.83 $37,720 - $72,406	-8,200 Reduced 4.79%	162,994 $857,000
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $938,478 - $1.22 Million	121,094 Added 241.7%	171,194 $1.46 Million
Q3 2021 Nov 10, 2021	SELL	$7.78 - $10.0 $31,898 - $41,000	-4,100 Reduced 7.56%	50,100 $498,000
Q2 2021 Jul 30, 2021	BUY	$9.22 - $14.48 $499,724 - $784,816	54,200 New	54,200 $505,000

Others Institutions Holding NUVB

# of Institutions

152

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $508M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Nuvation Bio Inc. Transaction History